Clinical trials: Placebo Group
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease.
- Trial name
- NCT02227693
- Testing
- avatrombopag
- Where
- 14 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Eisai Co., Ltd.
Asthma
TC-6987 for the Treatment of Mild to Moderate Asthma
This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
- Trial name
- NCT01296087
- Testing
- TC-6987
- Where
- 21 sites in United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not…
- Trial name
- OSKIRA - 2 (NCT01197534)
- Testing
- fostamatinib
- Where
- 149 sites in United States, Canada and 14 more
- Volunteers
- 913 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01494987
- Testing
- Ranolazine, Glimepiride, Diet
- Where
- 140 sites in United States, Czechia and 10 more
- Volunteers
- 431 people
- Sponsor
- Gilead Sciences
Overweight and Obesity, PreDiabetes
Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP
This study evaluates the effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP.
- Conditions
- Overweight and Obesity, PreDiabetes, Type2 Diabetes
- Trial name
- MATCH (NCT03622424)
- Testing
- Gelesis200
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Gelesis, Inc.
Hypogonadism, Androgens
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone…
- Trial name
- NCT00434824
- Testing
- Oral testosterone undecanoate (Andriol)
- Volunteers
- 322 people
- Sponsor
- Merck Sharp & Dohme LLC
Safety, Pharmacokinetics
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and biomarkers in blood when the drug is administered inhaled to healthy subjects
- Conditions
- Safety, Pharmacokinetics, Pharmacodynamics of AZD7594
- Trial name
- NCT01636024
- Testing
- AZD7594
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Tuberculosis
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection.
- Trial name
- NCT02581579
- Testing
- Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
Spasticity Due to Multiple Sclerosis
BX-1 in Spasticity Due to Multiple Sclerosis
To investigate the efficacy and safety of orally administered BX-1 compared to placebo in patients with spasticity due to multiple sclerosis not sufficiently controlled by current anti-spasticity medication
- Trial name
- NCT03756974
- Testing
- BX-1
- Where
- 40 sites in Czechia, Germany and 3 more
- Volunteers
- 397 people
- Sponsor
- Bionorica SE
Alzheimer's Disease
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease.
- Trial name
- WAY (NCT03790982)
- Testing
- AD-35 60 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Asthma
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of the two medications in one inhaler.
- Trial name
- NCT00657774
- Testing
- FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg
- Where
- 19 sites in United States
- Volunteers
- 160 people
- Sponsor
- SkyePharma AG
Obese, Obesity
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
- Trial name
- NCT07205900
- Testing
- HM15275
- Where
- 14 sites in United States
- Volunteers
- 267 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Achalasia
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), To assess the safety and tolerability To determine the effects on measures of…
- Trial name
- NCT02931565
- Testing
- Olinciguat
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cyclerion Therapeutics
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
This is a 3-part study. Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease.
- Trial name
- HUDSON GI (NCT05251909)
- Testing
- Benralizumab
- Where
- 20 sites in United States, Brazil and 7 more
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Pulmonary Disease, Chronic Obstructive
ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease
The study will be conducted in a respiratory specialist institute in Japan, with standardized techniques and data assurance checks to optimize data quality.
- Trial name
- NCT01607398
- Testing
- ADOAIR250
- Where
- 3 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis
Study Evaluating AGG-523 in Subjects With Osteoarthritis
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
- Trial name
- NCT00427687
- Testing
- AGG-523
- Where
- 3 sites in United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neuralgia, Postherpetic
RN624 For Pain Of Post-Herpetic Neuralgia
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
- Trial name
- NCT00568321
- Testing
- RN624
- Where
- 31 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.